Abstract: Objective To investigate the efficacy and security of urinarykallid in treatment of acute cerebral infarction and effects on nerve function. Methods Sixty patients with acute cerebral infarction were admitted to our hospital from May 2015 to May 2017. Patients were divided to treatment group and control group by the random number table. The control group was given conventional treatment. Patients in the treatment group were also given intravenous infusion of uninary kallid 0.15 U normal saline 100 mL once daily for 14 days. The blood routine, blood glucose, blood lipids, liver and kidney function, and myocardial enzymes before and after treatment were compared. And the efficacy and incidence of adverse drug reactions of two groups were observed. Results There were no significant changes in blood routine, liver and kidney function and myocardial function before and after treatment in the two groups, and there was no significant difference between the two groups after treatment (P>0.05). Two weeks after treatment, the NHISS score and the disability score were lower than those before treatment, and the treatment group was significantly better than the control group, the difference was statistically significant (P<0.05). At the end of the study. The difference was not statistically significant between the two groups (U=2.742，P=0.006). During the treatment, 2 cases of adverse reactions occurred in the treatment group (1 case of fever, 1 case of arrhythmia), the incidence rate was 6.7%; 3 cases of adverse reactions occurred in the control group (1 case of fever, 1 case of hypotension, 1 case of palpitations), occurred The rate was 10.0%, and the difference was not statistically significant (χ²=0.218, P=0.640). Conclusion Urinarykalid in treatment of acute brain infarction can effectively improve the nerve function of patients and improve the total treatment effectiveness of patients.